Welcome to our dedicated page for Invivyd news (Ticker: IVVD), a resource for investors and traders seeking the latest updates and insights on Invivyd stock.
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company focused on monoclonal antibody therapies for serious viral infectious diseases, beginning with SARS-CoV-2. The Invivyd news feed on Stock Titan highlights company announcements about clinical development, regulatory milestones, commercial performance, financing activities, and pipeline expansion.
Recent Invivyd news has featured updates on PEMGARDA (pemivibart), the company’s investigational monoclonal antibody authorized under a U.S. FDA emergency use authorization for pre-exposure prophylaxis of COVID-19 in certain immunocompromised adults and adolescents. The company reports quarterly PEMGARDA net product revenue and discusses uptake among healthcare providers caring for immunocompromised patients.
Investors also see frequent coverage of VYD2311, Invivyd’s vaccine-alternative monoclonal antibody candidate for COVID-19. News items describe FDA Fast Track designation, U.S. IND clearance, and the design of the Phase 3 DECLARATION trial within the broader REVOLUTION clinical program. Articles outline trial endpoints, intramuscular dosing regimens, and plans for pivotal data to support a potential Biologics License Application.
Beyond COVID-19, Invivyd’s news flow includes pipeline developments such as the selection of VBY329, a monoclonal antibody candidate for prevention of RSV infections in neonates, infants, and children, and discovery efforts targeting measles and other infectious diseases. Corporate news covers public offerings of common stock and pre-funded warrants, participation in healthcare conferences, and formation of the SPEAR Study Group to evaluate monoclonal antibody therapy for Long COVID and COVID-19 post-vaccination syndrome.
By following the IVVD news page, readers can review Invivyd’s official press releases and related updates in one place, including earnings announcements, clinical trial progress, regulatory designations, and capital-raising transactions.
Invivyd, formerly Adagio Therapeutics, announced a name change reflecting its focus on developing anti-viral antibodies that enhance immunity against viral diseases, starting with COVID-19. The company will trade under the new ticker symbol IVVD on Nasdaq starting September 13, 2022. Invivyd aims to deliver effective antibody solutions through its advanced discovery platform, which integrates evolutionary virology and antibody engineering. Additionally, the company is working on multiple candidates for seasonal influenza prevention.